Answers are grounded in this paper and cite their sources.
There are accumulating epidemiological, experimental, and genetic data supporting that prostate inflammation may contribute to prostate carcinogenesis, and several inflammatory-related molecules have been linked to tumorigenesis and prognosis in several tumors. The aim of this study was to evaluate tumor expression of inflammatory-related factors in prostate carcinomas and their possible relationship with biochemical recurrence (elevation of prostate-specific antigen serum levels). An immunohistochemical study was conducted using tissue microarrays and specific antibodies against interleukin-1β (IL-1β), IL-6, IL-10, IL-17, interferon β (IFNβ), and nuclear factor-κ B (NF-κB). Determinations in cancer specimens from 118 patients with primary prostate cancer (78 without and 40 with recurrence during the follow-up period) were performed. Immunostaining for all the studied proteins was localized both in tumor cells and in stromal cells in the majority of tumors. High-score values for IL-1β or low-score values for IFNβ were significantly associated with biochemical recurrence. The analysis defined a score value of 160 for IL-1β and of 170 for IFNβ as the optimal cutoff points that identified 32.7% and 73.2% of patients, respectively, having high probability of biochemical recurrence. Multivariate analysis according to a Cox model indicated that the cutoff point 170 for IFNβ (P=0.035) was an independent factor associated with biochemical recurrence in patients with prostate cancer. Both IL-1β and IFNβ may be new biomarkers to distinguish high-risk/low-risk patients with prostate cancer, and to select appropriate therapeutic approaches.
No takes yet. Share an insight, caveat, or question.
Eiró et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: